Abstract: The disclosure discloses an aryl hydrocarbon receptor modulators of formula (I), and pharmaceutically acceptable salts, R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra is independently H, or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring, or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom from N, O and S, or 4 to 7 membered non-aromatic heterocyclic ring containing 1 to 3 heteroatom from N, O and S and C?N, which are with no substituent or substituted by 1 or 3 R; Q is R, or a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom selected from N, O and S, which are with no substituent or substituted by 1 or 3 R; R is Rc connected with C or RN connected with N.

Abstract: The disclosure discloses an aryl hydrocarbon receptor modulators of formula (I), and pharmaceutically acceptable salts, R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra is independently H, or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring, or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom from N, O and S, or 4 to 7 membered non-aromatic heterocyclic ring containing 1 to 3 heteroatom from N, O and S and C?N, which are with no substituent or substituted by 1 or 3 R; Q is R, or a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom selected from N, O and S, which are with no substituent or substituted by 1 or 3 R; R is Rc connected with C or RN connected with N.

Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra are independently H or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is Rc which is C-attached or RN which is N-attached.

Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n?1, CnH2n?3, two Ra are independently H or two Ra together form =0 or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, 0, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, 0, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, 0, and S; and R is RC which is C-attached or RN which is N-attached.

Abstract: Methods of synthesizing 2?(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.

Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.